SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Geriatric Psychiatry and Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by McLendon, B. M.
Right arrow Articles by Doraiswamy, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLendon, B. M.
Right arrow Articles by Doraiswamy, P. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil Experience

Beth M. McLendon, PharmD

P. Murali Doraiswamy, MD

Regulatory guidelines in the US and Europe generally require that a drug specifically indicated for treating Alzheimer's disease (AD) must demonstrate an effect upon the core manifestations of dementia. Progressive cog nitive and functional losses are the cardinal features of AD. In the US, current guidelines require that new AD treatments show effectiveness on performance-based measures of cognition and on clinician-rated global assess ments. Improvement in function is also emphasized in the European guidelines. The primary instruments that have been used to evaluate changes in cognition and global function in most recent AD trials are the cognitive subscale of the Alzheimer's Disease Assessment Scale and a version of the Clinician's Interview Based Impression of Change, respectively. The results from three pivotal trials investigating the acetylcholinesterase inhibitor, donepezil, are used to demonstrate the way in which these tools are used, how to interpret the data they provide, and to deter mine their overall value in ascertaining efficacy in clinical practice. (J Geriatr Psychiatry Neurol 1999; 12:39-48).

Journal of Geriatric Psychiatry and Neurology, Vol. 12, No. 1, 39-48 (1999)
DOI: 10.1177/089198879901200108
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 FocusHome page
J. L. Cummings
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Focus, April 1, 2004; 2(2): 239 - 252.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
L. Demers, M. Oremus, A. Perrault, and C. Wolfson
Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Introduction
J Geriatr Psychiatry Neurol, December 1, 2000; 13(4): 161 - 168.
[Abstract] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
M. Oremus, A. Perrault, L. Demers, and C. Wolfson
Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Global Scales
J Geriatr Psychiatry Neurol, December 1, 2000; 13(4): 197 - 205.
[Abstract] [PDF]


Advertisement